Glow Protocol
Multi-Peptide Skin Rejuvenation Complex | Regenerative Blend
On this page
What is Glow Protocol?
The Glow Protocol combines three individually studied peptides, BPC-157, TB-500, and GHK-Cu, into a single formulation researched for skin- and tissue-related lab work. Each component has its own separate research literature, but the fixed-ratio combination itself has very little independent research of its own, so researchers are encouraged to check the individual peptide entries for the underlying data. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Glow Protocol is a peptide combination protocol.
The Glow Protocol is a peptide combination of BPC-157, TB-500, and GHK-Cu (Copper Peptide). It is commonly marketed as a research stack for skin rejuvenation and skin aging. Each individual component has its own research literature. Combination protocols still call for careful dosing consideration, so the studied range for each individual peptide is not exceeded.
Key research areas
- Combines three peptides with individual tissue-repair and skin research profiles into a single injection
Researched dosing
This table reflects how a combination protocol like this is typically structured in research and community practice, reference information for study design, not personal dosing guidance, since fixed ratios can push an individual component outside its own studied range.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Lower-dose studies | Calculate individual peptide amounts | Based on component requirements | Subcutaneous injection |
| Standard study protocol | Per supplier guidelines | As recommended | Subcutaneous injection |
| Single-peptide alternative | Separate peptides | Optimized schedules | Multiple injections |
How it works
At the cell level, research on this combination draws on each component's own studied pathway, BPC-157's anti-inflammatory signaling, TB-500's role in blood-vessel formation (angiogenesis), and GHK-Cu's effect on collagen-producing skin cells, rather than a single unified mechanism for the blend itself.
BPC-157 provides anti-inflammatory effects, TB-500 supports angiogenesis, and GHK-Cu stimulates collagen production. However, fixed-ratio combinations may deliver individual peptides outside their optimal therapeutic ranges.
What the studies report
This section lists the body systems and research areas associated with the three component peptides, a summary of what's been studied for each ingredient individually, not medical claims about people or about the combination as a whole.
Skin Health
GHK-Cu is studied for effects on collagen and elastin production, and is combined here with tissue-repair peptides in a single research stack. Multiple studies report increased collagen production associated with skin firmness and elasticity measures. The combination is marketed around several aging-related research pathways: collagen loss, tissue repair, and cellular regeneration.
Tissue Repair
BPC-157 and TB-500 are individually studied for wound-healing, anti-inflammatory, and angiogenesis effects relevant to tissue-repair research.
Cellular
The combination protocol is framed around cellular-regeneration pathways studied for the individual component peptides.
Dosage reference
- Doses used in research
- No single reference dose, blends vary by vial composition.
- Frequency in studies
- Depends on individual peptide requirements
- Handling
- Reconstituted solution, research use only; not for administration
- Timeline reported in studies
- Variable based on individual peptide doses
- Storage
- Refrigerate at 2-8°C, protect from light
- Cycle length
- Monitor individual peptide accumulation
- Break between cycles
- Based on component peptide requirements
Interactions
This list shows which other compounds researchers and formulators consider alongside this combination, including a caution about redundantly combining it with one of its own individual component peptides.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried combination powder into a liquid research solution, the same basic water-based mixing process used for single-peptide research, with an added note about verifying each component's labeled amount.
- Verify vial contents and individual peptide amounts before reconstitution
- Calculate target concentration based on individual peptide therapeutic doses
- Remove vial and bacteriostatic water from refrigeration, allow to reach room temperature
- Clean vial tops with alcohol swabs and allow to air dry completely
- Add calculated volume of bacteriostatic water for desired concentration
- Insert needle at angle, inject water slowly to avoid foaming
- Gently swirl until completely dissolved (do not shake vigorously)
- Label with reconstitution date, volume, and calculated individual peptide concentrations
Lyophilized: Refrigerated, use within Per manufacturer expiration date
Reconstituted: 2-8°C, use within 28 days
Open the Glow Protocol reconstitution calculatorQuality indicators
These are the visual and documentation checks researchers use to confirm a combination sample matches its labeled peptide amounts, the light blue tint from GHK-Cu's copper content is one visual cue specific to this blend.
Blue Solution - Solution should have a light blue hue from GHK-Cu copper content (intensity varies by concentration), clear without particles
Verify Peptide Content - Confirm individual peptide amounts match supplier specifications before use
Excessive Individual Peptide Amounts - Do not use if individual peptide doses exceed recommended therapeutic ranges
Proper Packaging - Vial should clearly state individual peptide amounts, not just total weight
Copper Discoloration - Temporary blue-green discoloration at injection sites is normal with GHK-Cu
Safety notes
This section covers handling cautions for combination protocols in a laboratory setting, chiefly the importance of calculating each component peptide's dose separately rather than assuming a fixed ratio is safe for every component, research-use-only scope, not medical safety advice for people.
- CRITICAL: Calculate individual peptide doses before starting any protocol
- Standard combination ratios may exceed therapeutic ranges for some peptides
- Start with minimal doses to assess individual peptide tolerance
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only, not for human or veterinary use.
What is not known
The limits of the published work on Glow Protocol, stated plainly. Research use only: none of this is guidance for a person.
No published study tests this three peptide combination at a fixed ratio. Everything quoted for it is drawn from work on one compound at a time.
Because nothing tests the mixture, how the three interact is not known. No paper reports whether one changes what another does, or what the ratio should be.
One rat study did test two of the three together, BPC-157 and TB-500, on a repaired Achilles tendon. The single compound groups did as well or better than the combination on the strength measure, so that study does not show that combining the two adds anything.
The skin claims attached to this combination come from separate work on the individual compounds, most of it in cells or animals.
There is no human trial of any of the three for skin, so this page does not show what the combination would do in a person.
The terms, in plain words
Every technical term this page leans on, said again in ordinary words.
- Fixed ratio combination
- A blend where the amount of each ingredient is set in advance.
- GHK-Cu
- A short peptide that carries a copper ion. Studied on its own in skin and wound research.
- In vitro
- In a dish, not in a living body.
- Protocol
- A written plan for a study: what is given, how much, and how often.
- Preclinical
- Done before any human study, so in cells or in animals.
Sources
The published work behind this entry. Each link was opened and each note says what that paper reports, not what it suggests.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 2026Thirty two rats with a cut and repaired Achilles tendon, in four groups: control, BPC-157, TB-500, and the two combined. The strength gain reached significance for TB-500 alone, not for the combination.
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats World Journal of Gastroenterology, 2004Rats. One of the single compound studies this combination borrows its reputation from. It tested BPC-157 on its own, on stomach ulcers, not skin.
How it is studied
In the published studies listed below. Each one names the species it was run in, the dose, how long it ran, and what it reported.
Research on BPC-157 individually shows wound healing and anti-inflammatory properties at specific therapeutic doses, forming the basis for inclusion in combination protocols.
TB-500 research shows tissue regeneration effects when dosed 2-5mg twice weekly, not daily as in some combination protocols.
Limited formal research exists on fixed-ratio peptide combinations, with most protocols based on clinical experience rather than controlled studies.